Physician profile
Ericka Searles
NPI 1053384412
$5,633.08
in general payments reported to CMS, 2019-2025
23 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.79 · 2020: $3,000 · 2021: $255 · 2022: $556 · 2023: $958 · 2024: $604 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.68 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,035.41 | 2019-2021 | |
| Abbvie INC. | $356.73 | 2019-2024 | Orilissa, Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $281.09 | 2023-2025 | Myfembree |
| Gynesonics, INC. | $269.51 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Myovant Sciences INC. | $237.37 | 2022 | |
| Hologic Sales and Service, LLC | $233.11 | 2021-2025 | Acessa Provu System, Omni Hysteroscope, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $232.17 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $182.41 | 2023-2025 | Veozah |
| Pfizer INC. | $175.91 | 2021-2024 | |
| Agile Therapeutics, INC. | $156.34 | 2022-2024 | Twirla |
| Exeltis, USA INC. | $103.47 | 2023-2025 | Slynd |
| Baxter Healthcare | $84.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.12 | 2022-2024 | |
| Millicent US INC | $42.34 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Covidien LP | $31.56 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $29.18 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $25.10 | 2024 | Orencia |
| Pacira Pharmaceuticals Incorporated | $21.90 | 2024 | Exparel |
| Coopersurgical, INC. | $20.00 | 2025 | Paragard T 380a |
| Convatec INC. | $18.78 | 2023 | |
| Scilex Pharmaceuticals INC. | $18.32 | 2024 | |
| Davol INC. | $17.48 | 2023 | Arista Ah Flexitip |
| Biogen, INC. | $16.13 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Searles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.